Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

Mutation-guided finite-duration acalabrutinib plus venetoclax for relapse after first-line finite-duration COVALENT Bruton tyrosine kinase inhibitor plus venetoclax‒based combination therapy in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma: Phase 2 MAVRiC study

View Full Paper
Ask AI
Bookmark
Share

Authors

MHMoana HodariJMJiefen MunleyRHRichard Hermann

Discussion

Loading...

Member takes

Overview

Phase 2 MAVRiC study shows improved progression-free survival in CLL patients after relapse, suggesting effective retreatment options.

Key Points

  • Retreatment with finite-duration venetoclax improved undetectable minimal residual disease rates in patients with chronic lymphocytic leukemia.
  • Progression-free survival and overall response rate are critical metrics evaluated after treatment with mutation-guided protocols.
  • Phase 2 MAVRiC study assesses the efficacy of acalabrutinib plus venetoclax in CLL patients with prior treatment.
  • Overall findings may highlight the need for mutation-guided therapy in addressing relapse in CLL patients.

Cite This Study

Hodari et al. (2025) studied this question.

synapsesocial.com/papers/69362f714fa91c937236e1bbhttps://doi.org/10.1182/blood-2025-3912
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Phase I/II study of acalabrutinib, venetoclax, and obinutuzumab in patients with relapsed/refractory and previously untreated Mantle Cell Lymphoma (MAVO)2025 · 8 citations
  2. 2Acalabrutinib plus venetoclax and rituximab in patients with treatment-naive (TN) mantle cell lymphoma (MCL): Results from the Phase 2 TrAVeRse study2025
  3. 3Outcomes with a fixed duration combination of bruton tyrosine kinase inhibitors and venetoclax in chronic lymphocytic leukemia: A systematic review and meta-analysis2025
  4. 4Impact of prognostic mutations on outcomes with fixed-duration acalabrutinib-venetoclax combinations versus chemoimmunotherapy: An exploratory analysis from AMPLIFY2025
  5. 5Zanubrutinib and venetoclax as initial therapy for CLL/SLL with obinutuzumab triplet consolidation in patients with detectable minimal residual disease (BruVenG).2025